VLVbio AB & Euro Diagnostica

VLVbio and Euro Diagnostica enters manufacturing collaboration



Due to the increased demand and expanding interest for apoptosis markers, VLVbio has submitted their manufacturing to the trusted custom manufacturing partner Euro Diagnostica.

The growing demand for VLVbio‘s apoptosis markers has created a need for additional high quality manufacturing capacity. Since this trend is expected to prevail, it is crucial for VLVbio to have a partner that can adapt manufacturing volumes accordingly. “The partnership with Euro Diagnostica secures product availability now and in the future independently of how the demand will grow. The manufacturing transfer procedure deployed by Euro Diagnostica required only 165 days from first contact to product availability, according to VLVbio specifications” says Richard Herrmann, CEO VLVbio AB.

更多新闻

  • PEVIVA® K18生物标志物与COVID-19

    新型冠状病毒SARS-CoV-2是造成目前全球性公共卫生危机的主凶,其致死率在2-6%之间,主要影响老年人和患有糖尿病、心脏病和高血压等潜在危险因素的人。

    查看更多
  • PEVIVA常见问题

    查看更多
  • PEVIVA M30与M65试剂盒联用,判断细胞死亡形式

    查看更多
  • 美国FDA鼓励利用CK-18作为药物性肝损伤生物标记物

    查看更多
  • PEVIVA相关资料

    查看更多
  • PEVIVA 肝损伤标记物CK-18检测试剂盒年底促销

    查看更多
  • NASH药物开发中的生物标志物

    使用CK18作为临床试验的次要终点

      非酒精性脂肪性肝病(NAFLD)是一种医学病症,其特征为肝脏中脂肪的沉积。NAFLD的范围从脂肪变性和非酒精性脂肪性肝炎(NASH)到纤维化NASH和...

    查看更多

© 2016-2017 富士胶片和光(广州)贸易有限公司 网站建设合优网络